Breast cancer drug not recommended for use in England

September 4, 2017, Cancer Research UK
Breast cancer drug not recommended for use in England
Credit: Cancer Research UK

The drug fulvestrant (Faslodex) has not been recommended in England to treat late stage breast cancer, in draft guidance.

The National Institute for Health and Care Excellence (NICE) has provisionally rejected fulvestrant for post-menopausal women with a form of the disease known as oestrogen-receptor positive.

Professor Arnie Purushotham, Cancer Research UK's senior clinical adviser, said that the decision was disappointing.

"Trials have shown that it can stall the 's growth, although the results don't yet show that it can improve survival," he said.

"We hope the manufacturer and NICE can work together to reach an agreement which allows the drug to be made available when NICE issues its final guidance."

The guidance covers women whose breast cancer is at a later stage or has spread to other parts of the body.

Fulvestrant works by blocking the hormone oestrogen, stopping its ability to cause some breast cancers to grow.

It would be used for postmenopausal women who haven't previously been treated with hormonal therapy such as aromatase inhibitors or tamoxifen.

Of the 32,000 diagnosed with breast cancer each year in England, it's estimated that up to 1,200 would be eligible for treatment with fulvestrant.

While NICE acknowledged that it can stall tumour growth by up to three months compared to , it said early evidence isn't strong enough to show that the drug extends survival.

A final decision will be made later in the year.

NICE said cheaper treatments are available which have more evidence for increasing survival.

The average cost of a course of fulvestrant is nearly £16,000.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said that while better treatments are needed for advanced , NICE has to ensure that those treatments offer value for money.

"As fulvestrant has not been shown to be cost-effective, we can't justify diverting NHS funds from other areas of healthcare in order to fund its use," she added.

Explore further: Breast cancer drug approved for NHS England

More information: Fulvestrant for untreated hormone-receptor positive metastatic breast cancer [ID951]. www.nice.org.uk/guidance/indev … ltation/html-content

Related Stories

Breast cancer drug approved for NHS England

June 16, 2017
The drug trastuzumab emtansine (Kadcyla) will soon be routinely available for patients in England with an advanced type of breast cancer.

Adding everolimus to fulvestrant improved outcomes for postmenopausal patients with HR-positive breast cancer

December 8, 2016
Progression-free survival was more than doubled for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy by adding everolimus (Afinitor) to treatment ...

Targeting estrogen receptor improves progression-free survival in advanced breast cancer

October 8, 2016
Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO ...

Anastrozole and fulvestrant combo better than single drug for metastatic breast cancer

August 1, 2012
Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic ...

New drug combination for advanced breast cancer delays disease progression

December 10, 2014
A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study (S6-03) ...

New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy

September 26, 2011
Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. Researchers ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.